Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer	C-Met Exon 14 Mutation	Recruiting	Phase 1 / Phase 2	2022-08-01		NCT04270591

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Haihe Biopharma Co., Ltd.	5

44 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of Hebei University	Baoding	China	1
Anhui province hospital	Hefei	China	7
Beijing Cancer Hospita	Beijing	China	1
Beijing Cancer Hospital	Beijing	China	8
Cancer Hospital Affiliated to Guangxi Medical University	Nanning	China	2
Cancer Hospital Affiliated to Harbin Medical University	Harbin	China	2
Changhai Hospital	Shanghai	China	4
Ehime University Hospital	Ehime	Japan	4
First Hospital of Jilin University	Changchun	China	14
Fudan University Shanghai Cancer Center	Shanghai	China	27
Hainan Cancer Hospital	Haikou	China	1
Henan Province Cancer Hospital	Zhengzhou	China	1
Hokkaido University Hospital	Sapporo	Japan	12
Hubei Cancer Hospital	Wuhan	China	3
Hunan Province Cancer Hospital	Changsha	China	1
Jiangsu Cancer Hospital	Nanjing	China	12
Jiangsu Province People's Hospital	Nanjing	China	2
Kanagawa Cancer Center	Kanagawa	Japan	5
Kindai University Hospital	Osaka	Japan	6
Kyushu University Hospital	Fukuoka	Japan	20
Liaoning Cancer Hospital	Shenyang	China	10
National Cancer Center	Tokyo	Japan	2
National Cancer Center Hospital East	Tokyo	Japan	1
Niigata Cancer Center Hospital	Niigata	Japan	10
Norton Cancer Institute	Louisville	United States	1

Clinical trials